drugset / Trial / NCT00533624

Myfortic vs. Cellcept in Kidney Transplant Recipients

NCT00533624

Phase 2/3 Completed 150 enrolled University of Miami Novartis Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The comparison the incidence of G.I. toxicity between Myfortic® vs. Cellcept® in 150 sequential patients, in which 75 will be randomized to Cellcept® and 75 to Myfortic® in first and second living or deceased donor renal transplant recipients.

Timeline

Start
2004-12
Primary completion
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mycophenolate Mofetil Small molecule 2000 mg
Comparator Mycophenolate Sodium Unknown 1440 mg